医学
多发性硬化
视神经脊髓炎
光谱紊乱
食品药品监督管理局
儿科
精神科
药理学
标识
DOI:10.7326/aitc202106150
摘要
Many groundbreaking advances have occurred in the field of multiple sclerosis since this series last reviewed the disorder in 2014. The U.S. Food and Drug Administration has approved 7 new medications for relapsing–remitting multiple sclerosis and approved the first medication for primary progressive multiple sclerosis. The McDonald criteria for diagnosing multiple sclerosis were updated in 2017. New blood tests can now differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder, and 3 new medications have been approved specifically for the latter disorder. Also, new medications for treating the symptoms of multiple sclerosis have been introduced.
科研通智能强力驱动
Strongly Powered by AbleSci AI